[Current therapeutic options in the management of superficial femoral artery occlusive disease: review of current evidence].
Decisions to treat SFA occlusions are increasingly being made irrespective of primary patency rates alone. Quality of life issues are increasingly taken into account when discussing treatment options with patients. Decisions to proceed with angioplasty and stenting of the SFA for TASC II C and D lesions will continue to be made. Reasons usually include patient or provider preference for minimally invasive treatments, the fact that surgery can usually proceed in similar fashion after failed endoluminal intervention, patients deemed too high risk for open surgical procedures, or infection at the proposed bypass site. This review of the evidence currently available considers the role of endovascular treatment and conventional surgery in the treatment of SFA occlusive disease.